Table 2.
Cohort characteristics, overall and by insurance type.
| All patients (N = 812) | Medicaid (n = 209, 25.7%) | Commercial (n = 603, 74.3%) | |
|---|---|---|---|
| Female gender, n (%) | 310 (38.2) | 81 (38.8) | 229 (38.0) |
| Median age in years (IQR) | 54 (49-59) | 54 (47-59) | 55 (50-59) |
| Non-White race, n (%) | 184 (22.7) | 107 (51.2) | 77 (12.8) |
| Median poverty prevalence in patient’s county (IQR) | 14 (12-17) | 16 (13-21) | 14 (11-16) |
| Year of diagnosis, n (%) | |||
| 2004-2005 | 52 (6.4) | 12 (5.7) | 40 (6.6) |
| 2006-2007 | 189 (23.3) | 43 (20.6) | 146 (24.2) |
| 2008-2009 | 302 (37.2) | 107 (51.2) | 195 (32.3) |
| 2010-2011 | 269 (33.1) | 47 (22.5) | 222 (36.8) |
| Provider NCI designation, n (%) | |||
| NCI | 163 (20.1) | 27 (12.9) | 136 (22.6) |
| Non-NCI | 637 (78.4) | 181 (86.6) | 456 (75.6) |
| Unknown | 12 | <11 | <11 |
| Cancer type, n (%) | |||
| Colorectal | 263 (32.4) | 54 (25.8) | 209 (34.7) |
| Head and neck | 311 (38.3) | 106 (50.7) | 205 (34) |
| Lung | 238 (29.3) | 49 (23.4) | 189 (31.3) |
| Location of first treatment day, n (%) | |||
| Hospital outpatient | 298 (36.7) | 79 (37.8) | 219 (36.3) |
| Physician office | 514 (63.3) | 130 (62.2) | 384 (63.7) |
| Number of drug contraindications, n (%) | |||
| 0 | 290 (35.7) | 73 (34.9) | 217 (36.0) |
| 1 | 356 (43.8) | 74 (35.4) | 282 (46.8) |
| ≥2 | 166 (20.4) | 62 (29.7) | 104 (17.2) |
| Selected contraindications, n (%) | |||
| Recent surgery | 355 (43.7) | 96 (45.9) | 259 (43.0) |
| Gastrointestinal bleeding or hemoptysis | 160 (19.7) | 54 (25.8) | 106 (17.6) |
| Brain metastasis | 76 (9.4) | 16 (7.7) | 60 (10.0) |
| Number of frailty indicators, n (%) | |||
| 0 | 541 (66.6) | 109 (52.2) | 432 (71.6) |
| 1 | 150 (18.5) | 45 (21.5) | 105 (17.4) |
| ≥2 | 121 (14.9) | 55 (26.3) | 66 (10.9) |
Drug contraindications and frailty indicators are shown in tabulated form because of low frequencies of many individual conditions which may result in possible reidentification due to cell sizes <11; selected contraindications with the greatest theorized potential to affect physician selection of high-price versus low-price treatments are shown individually.